Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Год журнала: 2024, Номер 1870(7), С. 167357 - 167357
Опубликована: Июль 20, 2024
Язык: Английский
Acta Oncologica, Год журнала: 2024, Номер 63, С. 385 - 391
Опубликована: Май 23, 2024
In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging experience from ongoing national initiatives that have already been particularly successful.
Язык: Английский
Процитировано
5
npj Precision Oncology, Год журнала: 2025, Номер 9(1)
Опубликована: Янв. 27, 2025
Publicly available trial matching tools can improve the access to therapeutic innovations, but errors may expose over-solicitation and disappointment. We performed a pragmatic non-interventional prospective evaluation on sequential patients at Molecular Tumor Board of Centre Leon Berard. During 10 weeks in 2024, we analysed 157 with four clinical from 19 screened: Klineo, ScreenAct, Trialing DigitalECMT. Each patient had 2.19 trials proposed average, 38% no suggested. The mean performances were precision = 0.33, recall 0.32, AP@3 0.45, NDCG@3 0.34. Using all increase 26% options. most frequent error concerned type gene variants required by selection criteria. showed that using Large Language Model patients' molecular reports could performance up 5%. recommend experts supervise results advocate for improved technologies.
Язык: Английский
Процитировано
0
Exploratory Research and Hypothesis in Medicine, Год журнала: 2024, Номер 000(000), С. 000 - 000
Опубликована: Июль 3, 2024
High-throughput proteomics has become an exciting field and a potential frontier of modern medicine since the early 2000s. While significant progress been made in technical aspects field, translating to clinical applications challenging. This review summarizes recent advances high-throughput discusses associated challenges, advantages, future directions. We focus on research breast cancer, bladder laryngeal squamous cell carcinoma, gastric colorectal coronavirus disease 2019. The application will face challenges such as varying protein properties, limitations statistical modeling, logistical difficulties data deposition, integration, harmonization, well regulatory requirements for validation considerations. However, there are several noteworthy advantages proteomics, including identification novel global networks, discovery new proteins, synergistic incorporation with other omic data. look forward participating embracing proteomics-based single-cell biology its applications, individualized pathology informatics, digital pathology, deep learning models proteomics. Several proteomic technologies noteworthy, data-independent acquisition mass spectrometry, nanopore-based 4-D secondary ion spectrometry. In summary, we believe drastically shift paradigm translational research, practice, public health near future.
Язык: Английский
Процитировано
3
Clinical and Translational Discovery, Год журнала: 2024, Номер 4(4)
Опубликована: Июль 12, 2024
Abstract Adenocarcinomas of the stomach and gastroesophageal junction remain one most common malignant tumours in humans worldwide, often with a poor prognosis. Particularly countries without upper gastrointestinal tract screening endoscopy, that have been asymptomatic for long time are only diagnosed at an advanced stage. This limits therapeutic options. Often palliative therapy concepts available. Great progress has made last two decades. The genetic basis adenocarcinomas deciphered new targeted drugs developed. Cell tissue‐based predictive diagnostics becoming increasingly important planning. Here, surgical pathology forms link between basic research, clinical trials, translation into application. review article summarizes experiences translational tumour which point to problems spatial temporal intratumoral heterogeneity gastroesophageal, development continuous re‐assessment therapeutically relevant cut‐off values, resistance mechanisms, microenvironment, sexual dimorphism pitfalls molecular boards may face.
Язык: Английский
Процитировано
0
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, Год журнала: 2024, Номер 1870(7), С. 167357 - 167357
Опубликована: Июль 20, 2024
Язык: Английский
Процитировано
0